Abstract:Importance: Multiple paclitaxel-based regimens are widely used in chemoradiation therapy against esophageal cancer, including regimens combining paclitaxel with fluorouracil, cisplatin, and carboplatin. However, which among these 3 regimens provides the best prognosis with minimum adverse events is still unknown.Objective: To compare the efficacy and adverse events of fluorouracil, cisplatin, and carboplatin in definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma (ESCC).Design, Setting, and Participants: This randomized clinical trial of patients with ESCC was conducted in 11 treatment centers in China. Eligible patients were aged 18 to 75 years and had histologically confirmed ESCC stages IIa to IVa with no prior treatment, Eastern Cooperative Oncology Group performance status of 2 or lower, and adequate organ functions. The study was conducted between July 2015 and February 2018, and the cutoff date for data analysis was August 31, 2020.Interventions: Patients with locally advanced ESCC were randomly assigned (1:1:1) to groups combining paclitaxel treatment with fluorouracil, cisplatin, or carboplatin. Patients in the cisplatin group were treated with 2 cycles of concurrent chemoradiotherapy followed by 2 cycles of consolidation chemotherapy with monthly paclitaxel plus cisplatin. For the fluorouracil group, patients were administered 6 cycles of weekly paclitaxel plus fluorouracil in concurrent chemoradiotherapy followed by 2 cycles of monthly paclitaxel plus fluorouracil in consolidation chemotherapy. Patients in the carboplatin group were treated with 6 cycles of weekly paclitaxel plus carboplatin in concurrent chemoradiotherapy followed by 2 cycles of monthly paclitaxel plus carboplatin in consolidation chemotherapy. All patients received radiotherapy of 61.2 Gy delivered in 34 fractions.Main Outcomes and Measures: The primary end point was overall survival (OS). The secondary end points were progression-free survival and adverse events.Results: Overall, 321 patients (median [IQR] age, 64 years [59-69 years]; 248 [77.3%] men) with ESCC from 11 centers were randomized into fluorouracil, cisplatin, or carboplatin groups between July 2015 and February 2018. Over a median (IQR) follow-up time of surviving patients of 46.0 months (36.6-53.0 months), the 3-year OS rates were 57.2% in the fluorouracil group, 60.1% in the cisplatin group, and 56.5% in the carboplatin group, respectively (fluorouracil vs cisplatin: HR, 1.06; 95% CI, 0.71-1.60; P = .77; fluorouracil vs carboplatin: HR, 0.94; 95% CI, 0.63-1.40; P = .77). The cisplatin group had significantly higher incidences of acute grade 3 or 4 neutropenia (69 events [60.8%] vs 19 [17.8%] for fluorouracil and 37 [34.6%] carboplatin; P < .001), thrombocytopenia (14 events [13.1%] vs 4 [3.7%] for fluorouracil and 5 [4.7%] for carboplatin; P = .01), anemia (50 events above grade 2 [46.7%] vs 25 [23.4%] for fluorouracil and 37 [34.6%] for carboplatin; P = .35), fatigue (11 events [10.3%] vs 2 [1.9%] for fluorouracil and 1 [0.9%] carboplatin; P = .007), and vomiting (17 events above grade 2 [15.9%] vs 3 [2.8%] for fluorouracil and 5 [4.7%] for carboplatin; P < .001) than the other 2 groups.Conclusions and Relevance: In this randomized clinical trial, paclitaxel plus fluorouracil did not show OS superiority over paclitaxel plus cisplatin or paclitaxel plus carboplatin regimens in definitive chemoradiation in patients with locally advanced ESCC. Higher rates of hematologic and gastrointestinal toxic effects were reported in the cisplatin group compared with those in the fluorouracil or carboplatin groups.Trial Registration: ClinicalTrials.gov Identifier: NCT02459457.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: among patients with locally advanced esophageal squamous cell carcinoma, which of the three paclitaxel - based chemotherapy regimens (paclitaxel combined with fluorouracil, cisplatin and carboplatin) can provide the best prognosis with the fewest adverse events? ### Research Background Esophageal cancer is one of the most common cancers in China, and most cases are squamous cell carcinomas. Concurrent chemoradiotherapy is the standard non - surgical treatment for locally advanced esophageal squamous cell carcinoma. Paclitaxel is an effective treatment drug for esophageal cancer and has been proven to enhance the effect of radiotherapy. However, there is no clear conclusion yet regarding the optimal regimen of paclitaxel combined with different chemotherapy drugs (such as fluorouracil, cisplatin and carboplatin). ### Research Objectives This study aims to compare the efficacy and adverse events of the three chemotherapy regimens of paclitaxel combined with fluorouracil, cisplatin and carboplatin in patients with locally advanced esophageal squamous cell carcinoma, in order to determine which regimen can provide the best prognosis with the fewest adverse events. ### Research Design This is a multi - center, open - label, randomized controlled phase III clinical trial. A total of 321 patients were enrolled and randomly divided into three groups to receive concurrent chemoradiotherapy with paclitaxel combined with fluorouracil, cisplatin or carboplatin respectively. The primary endpoint was overall survival (OS), and the secondary endpoints included progression - free survival (PFS) and adverse events. ### Main Results - **Overall Survival**: The 3 - year OS rates were 57.2% in the paclitaxel - combined - fluorouracil group, 60.1% in the paclitaxel - combined - cisplatin group, and 56.5% in the paclitaxel - combined - carboplatin group respectively. There were no significant differences among the groups. - **Adverse Events**: The incidences of hematological and gastrointestinal toxicity events in the cisplatin group were significantly higher than those in the other two groups, especially grade 3 or 4 neutropenia (69 cases vs 19 cases vs 37 cases), thrombocytopenia (14 cases vs 4 cases vs 5 cases) and vomiting (17 cases vs 3 cases vs 5 cases). ### Conclusion In this randomized controlled trial, paclitaxel combined with fluorouracil is not superior to paclitaxel combined with cisplatin or carboplatin regimens in terms of overall survival. However, the cisplatin group has a higher incidence of hematological and gastrointestinal toxicity events, leading to more treatment interruptions. Therefore, doctors need to comprehensively consider the patient's prognosis and the risk of adverse events when choosing a treatment regimen.

Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer

Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer A Randomized Clinical Trial

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial

Phase III Randomized Study of Preoperative Versus Postoperative Chemoradiotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

A Randomized Phase II/III Study of Paclitaxel/cisplatin Versus Cisplatin/5-Fluorouracil in Neoadjuvant Chemoradiotherapy (CRT) Followed by Surgery for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC).

Safety Results of a Phase III Randomized Trial of Comparison of Three Paclitaxel-Based Regimens Concurrent with Radiotherapy for Patients with Local Advanced Esophageal Squamous Cell Carcinoma (Eso-Shanghai 2)

Final Results of a Phase 3 Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma

Final Results of a Phase 3 Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma (Eso-Shanghai 1).

Improved Local Control by Surgery and Paclitaxel-Based Chemoradiation for Esophageal Squamous Cell Carcinoma: Results of a Retrospective Non-Randomized Study.

Systematic Review and Network Meta-Analysis: Neoadjuvant Chemoradiotherapy for Locoregional Esophageal Cancer

Paclitaxel and Carboplatin Versus Cisplatin and 5-Fluorouracil in Concurrent Chemoradiotherapy in Patients With Esophageal Cancer

Chemoradiotherapy with Paclitaxel Liposome Plus Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Analysis

Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).

A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma—the ESO-shanghai 1 trial protocol

Paclitaxel combined with platinum (PTX) versus fluorouracil combined with cisplatin (PF) in the treatment of unresectable esophageal cancer: a systematic review and meta-analysis of the efficacy and toxicity of two different regimens

Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial

Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis

144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

Comparative analyses of paclitaxel/carboplatin with cisplatin/5-fluorouracil-based chemoradiation in locally advanced inoperable upper and middle third esophageal cancer: A randomized prospective pilot study

A randomized, controlled, multicenter study of nab-paclitaxel plus cisplatin followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma (ESCC).